Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Recurrence 1Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Blast Crisis 1

Interventions

Cytarabine 561Azacitidine 385venetoclax 311Cyclophosphamide 289fludarabine 246fludarabine phosphate 229Decitabine 187Busulfan 176Daunorubicin 155Idarubicin 151Peripheral Blood Stem Cell Transplantation 138Mycophenolic Acid 134Filgrastim 134Whole-Body Irradiation 133Tacrolimus 125Granulocyte Colony-Stimulating Factor 124Etoposide 117Mitoxantrone 103Methotrexate 103Melphalan 103Cyclosporine 101Antilymphocyte Serum 85Gemtuzumab 84Clofarabine 84Specimen Handling 73Injections 69Stem Cell Transplantation 64Biopsy 57CPX-351 56Thiotepa 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × troxacitabine × Clear all
NCT00104468 2008-01-17

Study of Troxatylâ„¢ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)

SGX Pharmaceuticals, Inc.

Phase 1/2 Terminated
50 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00129948 2006-11-03

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

SGX Pharmaceuticals, Inc.

Phase 2 Terminated
211 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡